Coherus Biosciences appoints Michael Fleming as Senior Vice President, Commercial Strategy

28 April 2014

US biopharmaceutical company Coherus Biosciences has announced the appointment of Michael Fleming as Senior Vice President, Commercial Strategy.

Mr Fleming joins Coherus with more than 25 years of experience in strategic and operational leadership roles at preeminent biotech companies.

"Michael is a vital addition to the Coherus team at this time," said Denny Lanfear, president and chief executive of Coherus. "Our pipeline is now sufficiently advanced to begin evaluating our strategic options for commercialization. Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate importance. He will play a key role in defining strategies that effectively maximize the commercial potential of our products."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK